Drug company experts advised staff to withhold data about SSRI use in children
Open Access
- 2 March 2004
- journal article
- Published by CMA Impact Inc. in CMAJ : Canadian Medical Association Journal
- Vol. 170 (5) , 783
- https://doi.org/10.1503/cmaj.1040213
Abstract
An internal document advised staff at the international drug giant GlaxoSmithKline (GSK) to withhold clinical trial findings in 1998 that indicated the antidepressant paroxetine (Paxil in North America and Seroxat in the UK) had no beneficial effect in treating adolescents. ![Figure][1]Keywords
This publication has 0 references indexed in Scilit: